"ATTR amyloidosis was characterized by distinct patterns of functional impairment across all disease phenotypes, attributable to multiple physiological mechanisms. Multiple CPET parameters were ...
Please provide your email address to receive an email when new articles are posted on . In a small study, cardiopulmonary exercise testing identified significant abnormalities, including dysfunctional ...
The assessment of patients with suspected or confirmed pulmonary arterial hypertension (PAH) and secondary pulmonary hypertension (PH) continues to evolve and, in recent years, evidence demonstrating ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
In a recent study posted to the medRxiv* pre-print server, researchers demonstrated reduced exercise capacity due to persistent cardiopulmonary symptoms among coronavirus disease 2019 (COVID-19) ...
Correspondence to Dr Robert I Liem, Division of Hematology, Oncology & Stem Cell Transplant, Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA; rliem{at}luriechildrens.org ...
Many patients with symptoms of long COVID have reduced exercise capacity, which if better understood might be helpful in managing their treatment, according to a systematic review and meta-analysis of ...
A medical procedure that helps figure out why some people have a hard time breathing is now available to people here in Tulsa. Until now, people might have to wait years to get results and now, they ...
Correspondence to Dr Meagan M Wasfy, Cardiovascular Performance Program, Massachusetts General Hospital, Boston, MA 02114, USA; mwasfy{at}partners.org Objectives Persistent or late-onset ...
A recent document establishes standard operating procedures for exercise testing in patients with cystic fibrosis across the globe. It outlines tests that can be used in lower income countries. For ...
One study examines the small molecular cardiac myosin inhibitor for safety and efficacy at 96 weeks, and another compares it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback